<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35262642</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1462-0332</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Rheumatology (Oxford, England)</Title>
          <ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 86 cases including 23 French patients and systematic review.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">keac145</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keac145</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cryopyrin-associated periodic syndrome (CAPS) is a rare but treatable inherited autoinflammatory condition including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurologic cutaneous articular syndrome (CINCA). Our objective was to describe the main features of CAPS AA amyloidosis (AA-CAPS) associated and the efficacy of interleukin-1 inhibitors in this indication.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective study in France associated with a systematic literature review.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-six patients were identified: 23 new French cases and 63 from the literature, with a median age at amyloidosis diagnosis of 39 years old. CAPS subtypes were MWS (n=62), FCAS (n=9), frontier forms between MWS and FCAS (n=12) and between CINCA and MWS (n=3). NLRP3 had been sequenced in 60 patients (70%) and the most frequent mutation was R260W (60%). Three AA-CAPS patients displayed somatic NLRP3 mutations. Death occurred in 35 pa-tients (41%), none of whom having ever received interleukin-1 inhibitors. Twenty-eight patients (33%) received interleukin-1 inhibitors, with a &gt; 50% decrease in proteinuria in 89% of cases.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AA amyloidosis can occur in nearly all CAPS subtypes. Interleukin-1 inhibitors are effective, underlining the necessity of an early diagnosis of CAPS in order to start this treatment as soon as possible among AA-CAPS patients.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rodrigues</LastName>
            <ForeName>François</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, internal medicine department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cuisset</LastName>
            <ForeName>Laurence</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, Department of genetics, Cochin Hospital, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cador-Rousseau</LastName>
            <ForeName>Bérangère</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Médecine Interne, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giurgea</LastName>
            <ForeName>Irina</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, Département de Génétique Médicale, INSERM Childhood Genetic Diseases, AP-HP. Hôpital Trousseau, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neven</LastName>
            <ForeName>Benedicte</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, Department of rheumatologic pediatry, Necker hospital, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buob</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, Department of pathology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quartier</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Paris, Department of rheumatologic pediatry, Necker hospital, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hachulla</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lequerré</LastName>
            <ForeName>Thierry</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Normandie University, Rouen University Hospital, Department of Rheumatology &amp; CIC-CRB1404, INSERM, U1234, Rouen, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cam</LastName>
            <ForeName>Gérard</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Centre Hospitalier de Saint-Malo 35400 Saint-Malo France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boursier</LastName>
            <ForeName>Guilaine</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Rare and Autoinflammatory Genetic Diseases and Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA),CHU Montpellier,University of Montpellier, Montpellier, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hervieu</LastName>
            <ForeName>Valérie</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Department, Hopital Edouard Herriot, 5 Place d'Arsonval, 69003 Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grateau</LastName>
            <ForeName>Gilles</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, internal medicine department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Georgin-Lavialle</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, internal medicine department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Rheumatology (Oxford)</MedlineTA>
        <NlmUniqueID>100883501</NlmUniqueID>
        <ISSNLinking>1462-0324</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AA amyloidosis</Keyword>
        <Keyword MajorTopicYN="N">Cryopyrin associated periodic syndrome (CAPS)</Keyword>
        <Keyword MajorTopicYN="N">IL1 inhibitors</Keyword>
        <Keyword MajorTopicYN="N">NLRP3</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35262642</ArticleId>
        <ArticleId IdType="doi">10.1093/rheumatology/keac145</ArticleId>
        <ArticleId IdType="pii">6545281</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
